Scholars Central

Conference abstractPublished 5 Jul 2011

Stem cell therapy in acute myocardial infarction: a review of clinical trials

Authors: Jon C. George

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The myocardium had been viewed as a terminally differentiated organ without potential for regeneration until recently. Although early reperfusion strategies for occluded arteries in acute myocardial infarction (AMI) have greatly improved morbidity and mortality in these patients, further advances in treatment are limited by the inability to repair concomitantly damaged cardiac tissue. This has led to increasing use of stem cell therapies with the assumption that replacement or repair of damaged vascular and cardiac tissue could lead to improvement in myocardial function after AMI. Although multiple experimental animal models and clinical trials of cell based cardiac therapy have delivered promising results, the mechanisms of their effect are rather unclear. Stem cells (SC), depending on their lineage, possess the ability to differentiate into cells of various tissues. While the differentiation of SC into functional cardiomyocytes has been difficult to demonstrate and fraught with controversy, differentiation into functioning endothelium with improved blood flow has been better illustrated and accepted. Studies in animal models have demonstrated improvement in myocardial function after targeted repair of infarcted myocardium via implantation of endothelial progenitor cells by various delivery methods whether derived from peripheral blood (PB), bone marrow (BM), or umbilical cord blood (UCB). This has led to a variety of human clinical trials utilizing SC to determine safety , feasibility, and outcomes in the setting of AMI. Clinical trials in humans have primarily utilized autologous BM derived SC due to feasibility without concerns of yield as with PB derived cells and rejection as with UCB derived cells. Clinical trials of SC therapy in AMI can be classified into thre e major approaches of delivery: direct injection using an intracoronary route (IC), indirect cytokine-induced mobilization using granulocyte-colony stimulating factor (G-CSF), or a combination approach using initial mobilization followed by direct injection. However, interpretation of these trials has been difficult due to multiple variables including differences in trial design, cell type, timing of cell delivery, and outcome measurements.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical and Experimental Cardiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical and Experimental Cardiology
  • SubjectCardiology
  • BylineArticles whose byline prints “Jon C. George”